BlackRock’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-38,296
| Closed | -$4.98K | – | 5533 |
|
|
2025
Q3 | $4.98K | Sell |
38,296
-140,791
| -79% | -$19.3K | ﹤0.01% | 5268 |
|
|
2025
Q2 | $42.9K | Sell |
179,087
-4,599
| -3% | -$1.23K | ﹤0.01% | 5018 |
|
|
2025
Q1 | $36.2K | Hold |
183,686
| – | – | ﹤0.01% | 4981 |
|
|
2024
Q4 | $99K | Sell |
183,686
-99,940
| -35% | -$72.8K | ﹤0.01% | 4796 |
|
|
2024
Q3 | $270K | Buy |
283,626
+89,869
| +46% | +$102K | ﹤0.01% | 4462 |
|
|
2024
Q2 | $189K | Sell |
193,757
-95,931
| -33% | -$105K | ﹤0.01% | 4561 |
|
|
2024
Q1 | $458K | Buy |
289,688
+110,107
| +61% | +$133K | ﹤0.01% | 4388 |
|
|
2023
Q4 | $142K | Sell |
179,581
-1,086,543
| -86% | -$612K | ﹤0.01% | 4723 |
|
|
2023
Q3 | $988K | Buy |
1,266,124
+103,996
| +9% | +$87.3K | ﹤0.01% | 4246 |
|
|
2023
Q2 | $1.07M | Buy |
1,162,128
+278,161
| +31% | +$332K | ﹤0.01% | 4278 |
|
|
2023
Q1 | $964K | Sell |
883,967
-89,022
| -9% | -$138K | ﹤0.01% | 4347 |
|
|
2022
Q4 | $1.42M | Sell |
972,989
-441,258
| -31% | -$715K | ﹤0.01% | 4280 |
|
|
2022
Q3 | $1.52M | Buy |
1,414,247
+47,340
| +3% | +$87K | ﹤0.01% | 4318 |
|
|
2022
Q2 | $2.32M | Buy |
1,366,907
+36,068
| +3% | +$62K | ﹤0.01% | 4191 |
|
|
2022
Q1 | $2.74M | Buy |
1,330,839
+160,146
| +14% | +$432K | ﹤0.01% | 4258 |
|
|
2021
Q4 | $4.39M | Sell |
1,170,693
-90,179
| -7% | -$410K | ﹤0.01% | 4048 |
|
|
2021
Q3 | $6.52M | Buy |
1,260,872
+279,478
| +28% | +$1.25M | ﹤0.01% | 3856 |
|
|
2021
Q2 | $4.18M | Sell |
981,394
-512,952
| -34% | -$2.49M | ﹤0.01% | 3950 |
|
|
2021
Q1 | $7.93M | Buy |
1,494,346
+39,472
| +3% | +$226K | ﹤0.01% | 3701 |
|
|
2020
Q4 | $7.84M | Buy |
+1,454,874
| New | +$7.9M | ﹤0.01% | 3499 |
|
|
2019
Q4 | – | Sell |
-829,567
| Closed | -$1.25M | – | 4974 |
|
|
2019
Q3 | $1.25M | Buy |
829,567
+9,446
| +1% | +$22.1K | ﹤0.01% | 3898 |
|
|
2019
Q2 | $3.3M | Sell |
820,121
-4,077
| -0.5% | -$16.6K | ﹤0.01% | 3637 |
|
|
2019
Q1 | $3.54M | Sell |
824,198
-32,217
| -4% | -$150K | ﹤0.01% | 3528 |
|
|
2018
Q4 | $4.92M | Buy |
856,415
+81,010
| +10% | +$598K | ﹤0.01% | 3399 |
|
|
2018
Q3 | $10.5M | Buy |
775,405
+12,113
| +2% | +$127K | ﹤0.01% | 3215 |
|
|
2018
Q2 | $9.06M | Sell |
763,292
-43,660
| -5% | -$544K | ﹤0.01% | 3279 |
|
|
2018
Q1 | $9.06M | Buy |
806,952
+19,765
| +3% | +$173K | ﹤0.01% | 3172 |
|
|
2017
Q4 | $5.26M | Buy |
787,187
+785,387
| +43,633% | +$6.07M | ﹤0.01% | 3422 |
|
|
2017
Q3 | $15K | Buy |
+1,800
| New | +$11.2K | ﹤0.01% | 4635 |
|
|
2016
Q1 | – | Sell |
-600
| Closed | -$7K | – | 3636 |
|
|
2015
Q4 | $7K | Buy |
600
+430
| +253% | +$4.21K | ﹤0.01% | 3023 |
|
|
2015
Q3 | $2K | Hold |
170
| – | – | ﹤0.01% | 3160 |
|
|
2015
Q2 | $3K | Buy |
+170
| New | +$2.92K | ﹤0.01% | 3182 |
|
Other funds holding ADAP
JAIC
EF
RG
XT
BlackRock's ADAP Position: Q4 2025 in Review
BlackRock sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 38,296 shares — an estimated $4.98K sold.
BlackRock first reported a position in ADAP in Q2 2015 and held it in 32 quarters. The position peaked at $10.5M in Q3 2018. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.
- BlackRock reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
- BlackRock sold 38,296 Adaptimmune Therapeutics shares in Q4 2025, an estimated $4.98K.
- BlackRock first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 32 quarters.
- BlackRock's Adaptimmune Therapeutics position peaked at $10.5M in Q3 2018.
- 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.
Based on BlackRock's 13F filing for Q4 2025, filed 12 Feb 2026.